Top member reports
Consensus community valuation
$0.265
Average Intrinsic Value
61.0%
Undervalued by
Contributing Members
Sort by:
Recent
Create your free Strawman account to view member valuations
#ASX Announcements
Added 4 days ago

China NMPA Approves Uscom BP+

SYDNEY, Australia, Mon SYDNEY, Australia, Monday19th April,2021: Uscom Limited (ASX code: UCM) (the Company Company Company or Uscom) today notified the market that its patent protected high fidelity central blood pressure monitor, BP+, has received Chinese National Medical Products Administration (NMPA) approval for sale into China. The NMPA certificate will be issued within the next 10 working days.

The approval follows a rigorous 26 months’ process of testing and validation of the technology and now allows the Uscom BP+ to be sold in China, contributing a new sales revenue stream to Uscom.

View Attachment

Read More
#ASX Announcements
Added 3 months ago

27th January 2021

4C Quarterly Cash Report to 31 December 2020

  • Cash receipts $1.91m - up 149%
  • Sales revenue $0.98m – up 125%
  • Cash flow positive $0.29m
  • Cash on hand $2.28m, up $0.80m
Read More
#1/4ly Dec Result 27/1/21
Added 3 months ago

Cash receipts $1.91m - up 149%

Sales revenue $0.98m – up 125%

Cash flow positive $0.29m

Cash on hand $2.28m, up $0.80m

View Attachment

Read More
#ASX Announcements
stale
Added 6 months ago

Nice 4C today. 

My conversation with CEO  from Sept 2, 2020

 

Uscom (UCM) with Professor Robert Phillips, CEO

https://medicalmoney.com/episode32/

 

 

 

 

Read More
#Bull Case
stale
Added 11 months ago

Director buying on-market. This quarter's EPS will be very interesting - indications of large orders of USCOM 1A device to fit out 51 COVID Hospitals in China.

Read More